Marker Therapeutics Inc (MRKR)

[poods]

You have nailed it. CRs in pancreatic cancer with chemo are very rare. I can't add much to what you've said, but I will say this much. IMO people will be anxious to enter trials using Multi-TAA, either as an adjunct to chemo or as an adjuvant in the surgery setting. Why would they not. Absolutely nothing to lose and potentially so much to gain. We may get more of a hint this weekend or on Saturday as to how the adjuvant arm is doing. If they are not recurring it's very bullish. Alternatively if the ones that aren't recurring are showing T-cell expansion and epitope spreading, we'll know we're on the right track and Multi-TAA is active.